Clinical trial
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal…
NCT00138632 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00138632 |
|---|---|
| Title | Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) |
| Official title | A Randomized, Double-Masked, Multicenter, Phase I/II Study of the Safety of PTK787 Administered to Patients With Predominantly Classic , Minimally Classic or Occult With no Classic Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration |
| Acronym | ADVANCE |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Wet Age-Related Macular Degeneration |
| Intervention type | Drug |
| Interventions | PTK787, Placebo |
| Enrollment | 50 |
| Start date | Sep 1, 2005 |
| Primary completion | Nov 1, 2007 |
| First posted | Aug 30, 2005 |
| Last update posted | Nov 14, 2008 |
| Countries | Australia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: